icon-    folder.gif   Conference Reports for NATAP  
  IAS 2013: 7th IAS Conference on HIV
Pathogenesis Treatment and Prevention
June 30 - July 3 2013
Kuala Lumpur, Malaysia
Back grey_arrow_rt.gif
Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts)
  Reported by Jules Levin
IAS 2013 Kuala Lumpur June 30-July 3
R. Garraffo1, I. Poizot-Martin2, T. Lavrut1, L. Piroth3, S. Pol4, E. Bellissant5, E. Teicher, C. Solas2, M. Bourliere2, J-M. Molina6 and ANRS HC27 BOCEPREVIH Study Group
1.Nice University Hospital, France; 2. Marseille University Hospital, France; 3. Dijon University Hospital, France; 4. Paris, Cochin University Hospital, France; 5. Rennes University Hospital, France; 6. Paris, Saint Louis University Hospital, France
Conclusion : With the limitations of this small study, there was a trend towards lower ATV PK parameters when ATV/r was combined with BOC that was significant only for AUC. There was substantial variability in RAL PK parameters with a trend towards higher RAL AUC0-8h and Cmax and lower RAL Cτ which were not statistically significant. BOC PK was unaffected. Pending more data, carefully monitoring of HIV replication in pts under ATV/r or RAL-based regimens receiving BOC would be appropriate.